CN101428054A - Uses of rhodiola rosea in preventing and treating insulin resistance, and correlated metabolism diseases - Google Patents
Uses of rhodiola rosea in preventing and treating insulin resistance, and correlated metabolism diseases Download PDFInfo
- Publication number
- CN101428054A CN101428054A CNA2007101770174A CN200710177017A CN101428054A CN 101428054 A CN101428054 A CN 101428054A CN A2007101770174 A CNA2007101770174 A CN A2007101770174A CN 200710177017 A CN200710177017 A CN 200710177017A CN 101428054 A CN101428054 A CN 101428054A
- Authority
- CN
- China
- Prior art keywords
- radix rhodiolae
- extract
- application
- rhodiola
- insulin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses a Rhodiola L. and the application of the extract thereof as the drug used for preparing the insulin resistance and preventing and curing the relative metabolic diseases of diabetes, adiposis and the like; meanwhile, the invention discloses a preparation method for the extract; in addition, the invention further discloses the application of a pharmaceutical composition including the Rhodiola L. or (and) the Rhodiola L. extract as the drug and the health care product, and particularly discloses the application of the pharmaceutical composition used for preparing the drugs and the health care products for curing and preventing the insulin resistance and the relative metabolic diseases of diabetes, adiposis and the like.
Description
Technical field
The present invention relates to from Rhodida plant, extract the extract that can increase insulin sensitivity, this preparation method of extract, contain the maybe pharmaceutical composition of this genus extract of Rhodida plant, and Rhodida plant maybe should belong to extract and its pharmaceutical composition purposes as medicine, was particularly useful for preparing the medicine and the health product of metabolic diseases such as treatment and prevention insulin resistant and relevant diabetes thereof, obesity.
Background technology
Insulin resistant (insulin resistance) refer to body to the sensitivity of insulin and (or) the reactive reduction, be the main pathophysiological basis of metabolism syndrome, clinical closely related unusually with carbohydrate tolerance reduction, type 2 diabetes mellitus and complication thereof, obesity, blood fat disorder, non-alcoholic fatty liver disease, coronary heart disease etc.Metabolism syndrome is a series of chronic diseases, has developed into the big disease in third place in the world, and number increases year by year, not only has a strong impact on patient's quality of life, even threatens patient's life, and brings heavy financial burden to society.
Insulin is with after Insulin receptor INSR on the cell membrane combines, and a series of signal factor in the insulin signaling conducting system produces corresponding biological effect at last in the active cell.In the insulin signaling conducting system, many factors such as Insulin receptor INSR all activate because of tyrosine phosphorylation takes place; The factor after the activation dephosphorylation and inactivation under the effect of Protein-tyrosine-phosphatase, thus once circulation finished.PTP 1B (proteintyrosine phosphatase 1B, PTP1B) be one of important member in the protein phosphatase enzyme family, can make the tyrosine dephosphorylation of the phosphorylation of many activated signal factors such as Insulin receptor INSR, IRS, thereby the further transmission of termination signal is considered to one of important target spot of euglycemic agent.
Insulin resistant mechanism is very complicated, and correspondingly the action target spot of euglycemic agent is also very many.But it is the thiazolidinediones medicine of action target spot that the present euglycemic agent of using clinically is with PPAR γ.In addition, also there are lipid metabolism regulators such as traditional antidiabetic medicine such as report biguanides etc., the special class of shellfish etc. all to show the effect of certain increase body insulin sensitivity.
The representative drugs that medicament of insulin sensitizer has gone on the market has thiazolidinediones medicines such as rosiglitazone.The action target spot that the thiazolidinediones drug main is wanted is peroxidase paraphyte activated receptor γ (PPAR γ), can directly strengthen type 2 diabetes mellitus patient's liver, muscle and fatty tissue sensitivity to insulin, empty stomach and post-prandial glycemia are reduced, and do not cause hypoglycemia.Development in recent years is very fast, and troglitazone, rosiglitazone, pioglitazone listing are successively arranged.Troglitazone is withdrawn from market owing to serious liver toxicity (liver failure).The main side effect of such medicine is edema and weight increase.
Biguanides mainly contains metformin, phenformin.Though this type of medicine has been used for the treatment of diabetes at the end of the fifties, adverse reaction rate is very high, mainly contains significantly digestive tract side effects and lactic acid type poisonings such as gastrointestinal irritation, and its application is restricted.Particularly phenformin is because of its serious adverse effects, and a lot of countries forbid.
The medicinal history of Rhodida plant (Rhodiola L.) is long, and first in China doctor's allusion quotation " legendary god of farming's book on Chinese herbal medicine " just is called " medicine-feeding " of " support life with Ying Tian, nontoxic, obey clothes of a specified duration more and do not hurt sb.'s feelings, the QI invigorating of making light of one's life by commiting suicide, do not prolong life always " before more than 1000 year.In another ancient medicine monumental work Four-Volume Medical Code, also put down in writing the effect that Radix Rhodiolae has lung moistening, the kidney invigorating and regulates the flow of vital energy and nourish blood, can cure mainly cards such as the whole body is weak, uncomfortable in chest, body void.Among the people in Tibetan, then usually treat diseases such as cough, spitting of blood and gynecological with Radix Rhodiolae.The diseases such as clearing away lung-heat to relieve cough, hemostasis, traumatic injury, burn and scald, sexual impotence that are usually used among the people.Multiple functions such as studies show that in recent years, Radix Rhodiolae also have human body immunity improving power, health invigorating, improve the human body hematopoietic function, anti-hypoxia, defying age, antitumor, resisting fatigue, antiviral, radioprotective, prevention altitude sickness.
Bibliographical information is arranged, and Radix Rhodiolae saponin (Rhodosides) has triglyceride (TG), T-CHOL (TC), the low density lipoprotein, LDL (LDL-TC) effect of level in the aged Mus serum of reduction.Nuodikang (its composition is a Radix Rhodiolae) has triglyceride (TG), T-CHOL (TC), the low density lipoprotein, LDL (LDL-TC) effect of level in the high lipid diet of the reduction animal serum.The cell in vitro experiment shows that rhodioside can be by suppressing the differentiation of 3T3-L1 adipose cell.
Report proof is also arranged, through muscle, abdominal cavity and intravenous injection, but can not oral administration, Radix Rhodiolae polysaccharide can be brought into play the effect of certain blood sugar lowering by increasing insulin level in the blood, reducing the glucagon level.
Summary of the invention
The object of the invention is to provide the extract that extracts from Rhodida plant.
Another object of the present invention is to provide the method for this extract of preparation.
Another purpose of the present invention is to provide pharmaceutical composition, comprises carrier commonly used in Rhodida plant, Rhodida plant extract and the pharmaceutical field.
Another purpose of the present invention is to provide Rhodida plant and/or Rhodida plant extract, or the compositions that contains Rhodida plant and/or Rhodida plant extract has application in the insulin-sensitizing effect medicine in preparation.
Another purpose of the present invention is to provide Rhodida plant and/or Rhodida plant extract, or the compositions that contains Rhodida plant and/or extract has application in the insulin-sensitizing effect health product in preparation.
Another purpose of the present invention is to provide Rhodida plant and/or Rhodida plant extract, or contains the application of compositions in preparation treatment and prevention insulin resistant and correlated metabolism diseases medicine thereof of Rhodida plant and/or Rhodida plant extract.
Another purpose of the present invention is to provide Rhodida plant and/or Rhodida plant extract, or contains the application of compositions in preparation treatment and prevention insulin resistant and correlated metabolism diseases health product thereof of Rhodida plant and/or Rhodida plant extract.
In order to finish the present invention's purpose, can adopt following technical scheme:
Rhodida plant crude drug drying and suitable pulverizing to increase the contact area of medical material and solvent, are raised the efficiency.The extraction solvent of crude drug makes the mixture of water, alcohols or water and alcohols.Preferred alcohols comprises ethanol.The mixture of water and alcohols for example contains the water of alcohol compound 40%-98% (volume ratio).During extraction quantity of solvent be former medicine weight 4-14 doubly.Extraction can be static or down dynamic, preferably under dynamic condition.The temperature of extracting be from room temperature (for example 20 ℃) to the scope of solvent refluxing temperature in, preferably under the temperature of backflow.Extraction can be carried out continuously or intermittently, can repeat 1-4 time during intermittent extraction.
After above-mentioned steps finishes, merging filtrate, filtrate concentrates at normal pressure or decompression heating under dynamical state.
Filtrate is merged further concentrating,
Extract can become dry powder through lyophilization.
Product of the present invention comprises medicine and health product.
Radix Rhodiolae of the present invention is Crassulaceae rhodiola (Rhodio/a L.) plant, comprises Radix Rhodiolae, Folium Trapae Radix Rhodiolae, slender lobule Radix Rhodiolae, Radix Rhodiolae, Rhodiola kirilowii (Regel) Maxim..
The medicinal part that extracts with the crude drug Radix Rhodiolae is a herb, and aerial parts and root, Radix Rhodiolae extract preferably obtain from its herb.
The invention still further relates to and contain as the extract of the present invention of active ingredient and the pharmaceutical composition of conventional medicine excipient or adjuvant.Usually pharmaceutical composition of the present invention contains the extract of the present invention of 0.1-95% weight.
The present invention also provides a kind of pharmaceutical composition, and it comprises medicine effective dose, as active component as the inventive method Rhodida plant and/or Rhodida plant extract and pharmaceutically acceptable carrier.
The pharmaceutical composition of extract of the present invention can be according to method preparation well known in the art.When being used for this purpose, if desired, extract of the present invention and one or more solids or liquid medicine excipient and/or adjuvant can be combined, make and can be used as suitable administration form or the dosage form that people's medicine or veterinary drug use.
Extract of the present invention or contain its pharmaceutical composition can the unit dosage form administration, route of administration can be intestinal or non-intestinal, as oral, nasal cavity, oral mucosa, skin, peritoneum or rectally etc., preferred oral administration.
Extract of the present invention or contain the route of administration of its pharmaceutical composition comprises drug administration by injection equally.Injection comprises intravenous injection, intramuscular injection, subcutaneous injection, intradermal injection etc.
Form of administration can be liquid dosage form, solid dosage forms.As liquid dosage form can be true solution class, colloidal type, particulate formulations, emulsion dosage form, mixed suspension form.Other dosage forms are tablet, capsule, drop pill, aerosol, pill, powder, solution, suspensoid, Emulsion, granule, suppository, lyophilized injectable powder etc. for example.
Extract of the present invention can be made ordinary preparation, also can be slow releasing preparation, controlled release preparation, targeting preparation and various particulate delivery system.
For the unit form of administration is made tablet, can be extensive use of various carrier well known in the art.Example about carrier is, for example diluent and absorbent are as starch, dextrin, calcium sulfate, lactose, mannitol, sucrose, sodium chloride, glucose, carbamide, calcium carbonate, kaolin, microcrystalline Cellulose, aluminium silicate etc.; Wetting agent and binding agent are as water, glycerol, Polyethylene Glycol, ethanol, propanol, starch slurry, dextrin, syrup, Mel, glucose solution, mucialga of arabic gummy, gelatine size, sodium carboxymethyl cellulose, lac, methylcellulose, potassium phosphate, polyvinylpyrrolidone etc.; Disintegrating agent, for example dry starch, alginate, agar powder, laminaran, hydrocarbon sodium and citric acid, calcium carbonate, polyoxyethylene sorbitol fatty acid ester, dodecyl sodium sulfate etc.; Lubricant, for example Pulvis Talci, silicon dioxide, corn starch, stearate, boric acid, liquid paraffin, Polyethylene Glycol etc.Tablet further can also be made coated tablet, for example sugar coated tablet, thin membrane coated tablet, ECT, or double-layer tablet and multilayer tablet.
For example, can be extensive use of various carrier well known in the art for pill is made in the administration unit.Example about carrier is, for example diluent and absorbent are as glucose, lactose, starch, cocoa butter, hydrogenated vegetable oil, polyvinylpyrrolidone, Gelucire, Kaolin, Pulvis Talci etc.; Binding agent, as arabic gum, Tragacanth, gelatin, ethanol, Mel, glucose solution, mucialga of arabic gummy, gelatine size, sodium carboxymethyl cellulose, lac, methylcellulose, potassium phosphate, polyvinylpyrrolidone etc.; Disintegrating agent, for example dry starch, alginate, agar powder, laminaran, hydrocarbon sodium and citric acid, calcium carbonate, polyoxyethylene sorbitol fatty acid ester, dodecyl sodium sulfate, methylcellulose, ethyl cellulose etc.; Disintegrate inhibitor, for example sucrose, glyceryl tristearate, cocoa butter, hydrogenation wet goods; Absorption enhancer, for example quaternary ammonium salt, stearate, boric acid, liquid paraffin, Polyethylene Glycol etc.Tablet further can also be made coated tablet, for example sugar coated tablet, thin membrane coated tablet, ECT, or double-layer tablet and multilayer tablet.
For example, can be extensive use of various carrier well known in the art for pill is made in the administration unit.Example about carrier is, for example diluent and absorbent are as glucose, lactose, starch, cocoa butter, hydrogenated vegetable oil, polyvinylpyrrolidone, Gelucire, Kaolin, Pulvis Talci etc.; Binding agent is as arabic gum, Tragacanth, gelatin, ethanol, Mel, liquid sugar, rice paste etc.Disintegrating agent is as agar powder, dry starch, alginate, dodecyl sodium sulfate, methylcellulose etc.For example for capsule is made in the administration unit, effective ingredient the present invention is carried thing mix, and the mixture that will obtain thus places hard gelatine capsule or soft capsule with above-mentioned various carriers.Also effective ingredient extract of the present invention can be made microcapsule, be suspended in and form suspensoid in the aqueous medium, in the hard capsule of also can packing into or make injection and use.
For example, extract of the present invention is made injection preparation, as solution, suspensoid solution, Emulsion, lyophilized injectable powder, this preparation can be moisture or non-water, can contain acceptable carrier, diluent, binding agent, lubricant, antiseptic, surfactant or dispersant on a kind of and/or multiple pharmacodynamics.Can be selected from water, ethanol, Polyethylene Glycol, 1 as diluent, the isooctadecanol of ammediol, ethoxylation, the isooctadecanol of polyoxyization, Polyoxyethylene Sorbitol Fatty Acid Esters etc.In addition, ooze injection and hit liquid, can in injection preparation, add proper amount of sodium chloride, glucose or glycerol, in addition, can also add conventional cosolvent, buffer agent, PH regulator etc. in order to prepare etc.These adjuvants are that this area is commonly used.In addition, as needs, also can in pharmaceutical preparation, add coloring agent, antiseptic, spice, correctives, sweeting agent or other material.
For reaching the medication purpose, strengthen therapeutic effect, medicine of the present invention or pharmaceutical composition can be with any known medication administrations.
The dosage of extract pharmaceutical composition of the present invention depends on many factors, for example to prevent or treat the character and the order of severity of disease, the sex of patient or animal, age, body weight, personality and individual reaction, route of administration, administration number of times, therapeutic purposes, therefore therapeutic dose of the present invention can have large-scale variation.In general, the using dosage of Chinese materia medica composition of the present invention is well known to a person skilled in the art.The actual drug quantity that can be according to the present invention be contained in the last preparation in the extractive composition, in addition suitable adjustment to reach the requirement of its treatment effective dose, is finished prevention of the present invention or therapeutic purposes.The consumption of the suitable dose scope extract of the present invention of the every day of extract of the present invention is 0.001-100g crude drug/kg body weight, is preferably 0.01-50g crude drug/kg body weight, most preferably is 0.05-25g crude drug/kg body weight.Above-mentioned dosage can the single dose form or is divided into severally, and for example the administration of two, three or four dosage modes is subject to administration doctor's clinical experience and comprises the dosage regimen of using other treatment means.Each treats that required accumulated dose can be divided into repeatedly or by the dose administration.Extract of the present invention or compositions can be taken separately, or merge use and adjust dosage with other treatment medicine or symptomatic drugs.
To the IR mice with metabolism syndrome features such as insulin resistants of diet induced, Radix Rhodiolae extract has the tangible effect that improves insulin resistant, and PTP1B is one of its action target spot.
Description of drawings
Fig. 1. Radix Rhodiolae extract is to influence (n=10.#, ##, ###, p＜0.05,0.01, the 0.001 vs Con of exogenous insulin load back blood glucose;
*,
*,
* *, p＜0.05,0.01,0.001 vs IR.)
Fig. 2. Radix Rhodiolae extract is to influence (n=10.###, the p＜0.001vs Con of area under the blood glucose-time graph of insulin load back;
*,
* *, p＜0.01,0.001vs IR.)
Fig. 3. Radix Rhodiolae extract is to influence (n=10.#, ##, p＜0.05,0.01vsCon to change of blood sugar behind the glucose load;
*,
*, p＜0.05,0.01vs IR.)
Fig. 4. Radix Rhodiolae extract to glucose load after influence (n=10.##, the p＜0.01vs Con of area under blood glucose-time graph;
*,
*, p＜0.05,0.01vs IR.)
Fig. 5. Radix Rhodiolae extract is to influence (n=10.###, the p＜0.001 vs Con of glucose infusion speed GIR during stable state in the experiment of the positive sugar pincers of IR mice;
* *, p＜0.001vs IR.)
The specific embodiment
The preparation of preparation example Radix Rhodiolae extract
Pharmacological evaluation
Embodiment 1. Radix Rhodiolae extracts are to the influence of the plain tolerance of insulin resistant IR mouse islets
Method:
Use high-sugar-fat-diet, feed C57BL mouse and form insulin resistant mouse model (IR).Animal pattern is divided into 3 groups at random, is respectively animal pattern matched group (IR), positive control drug rosiglitazone group (rosiglitazone) and Radix Rhodiolae extract group, respectively oral water, rosiglitazone 15mg/kg and Radix Rhodiolae extract 2g/kg.The same crowd of intact animal who establishes simultaneously to normal forage feed makes normal control group (Con).Give animal subcutaneous injection 0.4U/kg insulin, observe insulin load back changes of blood glucose, and calculate area (AUC) under blood glucose-time graph, i.e. insulin tolerance experiment (ITT).
The result:
With insulin resistant animal successive administration 10days, carry out the ITT experiment.The result shows (Fig. 1), compares with normal control Con group, and insulin load back each time point blood glucose of IR treated animal descends and all obviously increases, and demonstrates the obvious insulin resistance phenomenon.Compare with the IR animal pattern, each time point blood glucose decline percentage number average of rosiglitazone group insulin load back obviously reduces, and illustrates that animal obviously increases the sensitivity of insulin; Each time point blood glucose of Radix Rhodiolae extract treated animal insulin load back all decreases, and all obviously reductions of low valley of 30min blood glucose and 120min blood sugar recovery value, and area (AUC) obviously reduces (Fig. 2) under blood glucose-time graph.This effect is similar with the effect of euglycemic agent rosiglitazone, illustrates that Radix Rhodiolae extract has certain insulin-sensitizing effect to the IR mice.
Method:
Use high-sugar-fat-diet, feed C57BL mouse and form insulin resistant mouse model (IR).Animal pattern is divided into 3 groups at random, is respectively animal pattern matched group (IR), rosiglitazone group and Radix Rhodiolae extract group, respectively oral water, positive control drug rosiglitazone 15mg/kg and Radix Rhodiolae extract 2g/kg.Simultaneously with feeding as normal control group (Con) with normal diet with batch C57BL mouse.Successive administration 7days gives animal oral glucose 2g/kg, changes of blood glucose behind the observation animal glucose load, and calculate area (AUC) under blood glucose-time graph, i.e. oral glucose tolerance experiment (OGTT).
The result:
The result shows (Fig. 3), compares with Con, and each time point blood glucose of IR treated animal all obviously raises, and demonstrates tangible glucose tolerance and lowers phenomenon.Compare with the IR treated animal, each time point blood glucose all obviously reduces behind the rosiglitazone group glucose load, demonstrates the obvious effect that improves the glucose tolerance of animal; Each time point blood glucose all obviously reduces behind the Radix Rhodiolae extract treated animal glucose load, and all obviously reductions of 30min glycemic peaks and 120min blood sugar recovery value, and area AUC obviously reduces (Fig. 4) under blood glucose-time graph.This effect is similar with the effect of euglycemic agent rosiglitazone, illustrates that Radix Rhodiolae extract is to the have some improvement effect of glucose tolerance of body of insulin resistant mice tool.
Embodiment 3. Radix Rhodiolae extracts are to the influence of glucose infusion speed GIR during stable state in the experiment of the positive sugar pincers of insulin resistant IR mice
Method:
Use high-sugar-fat-diet, feed C57BL mouse and form insulin resistant mouse model (IR).Animal pattern is divided into 3 groups at random, is respectively animal pattern matched group (IR), rosiglitazone group and Radix Rhodiolae extract group, respectively oral water, positive control drug rosiglitazone 15mg/kg and Radix Rhodiolae extract 2g/kg.Simultaneously with feeding as normal control group (Con) with normal diet with batch C57BL mouse.Successive administration 20～25days carries out hyperinsulinism clamp (the positive sugar pincers) experiment of normal glucose level.Be animal fasting 4 hours, weigh, 37 ℃ of temperature-constant plates are fixed in the anesthesia of lumbar injection pentobarbital sodium, operation separates jugular vein, intubate behind the input 1000U/ml anticoagulant heparin, connects microsyringe (COLE PARMER, 789100C, the U.S.) with constant speed gasing injection insulin 60pmol/kg/min and micro-peristaltic pump (ISMATEC, 78001-00, the U.S.) with variable bit rate infusion 10% glucose solution; Operation separates carotid artery, to be on the waiting list blood.Get blood every 10min, with blood glucose meter (BIOSEN 5030, Germany) monitoring blood sugar level.Regulate glucose infusion speed according to blood sugar level, make glucostasis in 95 ± 5mg/dl scope, after blood glucose was stablized 30min at least, 3 glucose infusion speed of METHOD FOR CONTINUOUS DETERMINATION were averaged as glucose infusion speed (GIR) during stable state in the positive sugar pincers experiment of animal.
The result:
In the hyperinsulinism clamp of normal glucose level (the positive sugar pincers) experiment during stable state glucose infusion speed GIR value be the golden index of generally acknowledged at present evaluation insulin resistant.Experimental result demonstration (Fig. 5) in the experiment of positive sugar pincers, is compared with Con, and IR treated animal GIR level obviously reduces, and illustrates that this animal pattern has had obvious insulin resistance.Compare with the IR animal pattern, euglycemic agent rosiglitazone and Radix Rhodiolae extract make the GIR level improve 277.9% and 106.9% respectively.Illustrate that Radix Rhodiolae extract and rosiglitazone are similar, all have of the effect of the IR mice of obvious increase insulin resistant the sensitivity of exogenous insulin.
Embodiment 4. Radix Rhodiolae extracts are to the inhibitory action of gene recombinant human PTP1B
Method:
Utilize the BL21E.Coli escherichia coli to prepare the people PTP1B engineering bacteria of gene recombinaton, and use GST affinity column purifying protein, obtain PTP1B albumen.With nitro phosphate is substrate, carries out the zymetology reaction of PTP1B, and the observation in vitro medicine is to the influence of PTP1B protein active.
The result:
Radix Rhodiolae extract suppression ratio to the people PTP1B of gene recombinaton when final concentration is 10 μ g/ml is 89.3%; Its concentration (IC50) to 50% suppression ratio of PTP1B is 1.436 μ g/ml.Illustrate that Radix Rhodiolae extract has certain inhibitory action to PTP1B (one of euglycemic agent target spot).
Claims (7)
1. the application of Rhodida plant in preparation euglycemic agent product.
2. the application of Rhodida plant in the product of metabolic diseases such as preparation treatment and prevention insulin resistant and relevant diabetes, obesity.
3. according to the arbitrary described application of claim 1-2, it is characterized in that described Radix Rhodiolae is Crassulaceae rhodiola (Rhodiola L) plant, comprises Radix Rhodiolae, Folium Trapae Radix Rhodiolae, slender lobule Radix Rhodiolae, Radix Rhodiolae, Rhodiola kirilowii (Regel) Maxim..
4. the application of Radix Rhodiolae extract in preparation euglycemic agent product.
5. the application of Radix Rhodiolae extract in the product of metabolic diseases such as preparation treatment and prevention insulin resistant and relevant diabetes, obesity.
6. according to the application of claim 4-5, described Radix Rhodiolae extract is prepared by following method, and Radix Rhodiolae is dried and crushed into coarse powder; Coarse powder water or 40-98% ethanol extraction, extracting solution gets Radix Rhodiolae extract through concentrated, dry.
7. according to the application of claim 6, it is characterized in that described Radix Rhodiolae is Crassulaceae rhodiola (Rhodiola L.) plant, comprises Radix Rhodiolae, Folium Trapae Radix Rhodiolae, slender lobule Radix Rhodiolae, Radix Rhodiolae, Rhodiola kirilowii (Regel) Maxim..
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007101770174A CN101428054A (en) | 2007-11-08 | 2007-11-08 | Uses of rhodiola rosea in preventing and treating insulin resistance, and correlated metabolism diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007101770174A CN101428054A (en) | 2007-11-08 | 2007-11-08 | Uses of rhodiola rosea in preventing and treating insulin resistance, and correlated metabolism diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101428054A true CN101428054A (en) | 2009-05-13 |
Family
ID=40643822
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2007101770174A Pending CN101428054A (en) | 2007-11-08 | 2007-11-08 | Uses of rhodiola rosea in preventing and treating insulin resistance, and correlated metabolism diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101428054A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103845634A (en) * | 2012-12-04 | 2014-06-11 | 中国医学科学院药物研究所 | Application of Cymbopogon plant extractive as insulin sensitizing medicine |
| WO2015067216A1 (en) * | 2013-11-08 | 2015-05-14 | Chi-Ying Huang | Novel use of a dimethyl sulphoxide (dmso) extract or fraction from graptopetalum sp. |
-
2007
- 2007-11-08 CN CNA2007101770174A patent/CN101428054A/en active Pending
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103845634A (en) * | 2012-12-04 | 2014-06-11 | 中国医学科学院药物研究所 | Application of Cymbopogon plant extractive as insulin sensitizing medicine |
| CN103845634B (en) * | 2012-12-04 | 2019-12-13 | 中国医学科学院药物研究所 | application of citronella plant extract as insulin sensitizing drug |
| WO2015067216A1 (en) * | 2013-11-08 | 2015-05-14 | Chi-Ying Huang | Novel use of a dimethyl sulphoxide (dmso) extract or fraction from graptopetalum sp. |
| CN105813646A (en) * | 2013-11-08 | 2016-07-27 | 黄奇英 | Novel use of a dimethyl sulphoxide (dmso) extract or fraction from graptopetalum sp. |
| TWI681774B (en) * | 2013-11-08 | 2020-01-11 | 黃奇英 | Novel use of a dimethyl sulphoxide (dmso) extract or fraction from graptopetalum sp |
| CN105813646B (en) * | 2013-11-08 | 2020-07-28 | 黄奇英 | Novel use of a dimethyl sulfoxide extract or fraction from Trionyx |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102526165B (en) | A kind of Radix Rhodiolae effective site, its preparation method, its pharmaceutical composition and purposes | |
| CN101264122B (en) | Hypericum extract, its making method and medicinal composition and use for treating diabetes | |
| CN102526164B (en) | The Chinese medicine composition of control insulin resistant and associated metabolic syndrome thereof | |
| CN101347422B (en) | Uses of salvianolic acid A in preventing and/or treating diabetes and complication | |
| CN1965873B (en) | Chinese medicinal extract having blood sugar-lowering activity, its preparation process, composition and use | |
| CN101601780A (en) | The application of Chinese violet in anti-diabetic and control correlated metabolism diseases | |
| CN102145060A (en) | Dual-cordis effect of Xin Keshu | |
| CN104857154A (en) | Traditional Chinese medicine composition for treating three-high diseases and preparation method therefor | |
| CN101099753A (en) | Preparation method and application for general saponin of cortex ilecis rotundae | |
| CN103342726A (en) | Preparation method and application of camellia flavonoid for reducing blood glucose | |
| CN102716135B (en) | Lupenone prevents in preparation or treats the application in the product of diabetes | |
| CN109125315A (en) | Composition and purposes with hypoglycemic, reducing blood lipid and hypotensive activity | |
| CN101433598A (en) | Uses of giant knotweed for preventing and treating insulin resistance and related metabolic diseases thereof | |
| CN101428055A (en) | Uses of rhodiola rosea plants in medicament for preventing and treating diabetes and adiposis | |
| CN101428054A (en) | Uses of rhodiola rosea in preventing and treating insulin resistance, and correlated metabolism diseases | |
| CN103906525B (en) | Principal columns of a hall tree extract is preparing the application in treating Gastric Ulcer Treatment | |
| CN103055176B (en) | Traditional Chinese medicine for treating diabetes mellitus and preparation method thereof | |
| CN105031248B (en) | It is a kind of containing selenium worm grass can auxiliary hyperglycemic health care product | |
| CN103845634B (en) | application of citronella plant extract as insulin sensitizing drug | |
| CN102225082B (en) | Medicament for preventing and treating diabetes and complications thereof and preparation method thereof | |
| CN112089784A (en) | Application of traditional Chinese medicine composition in preparation of medicine for preventing and treating diseases caused by atherosclerosis | |
| CN106109951A (en) | Prevent and treat medicine of hyperglycemia, hyperlipidemia, hypertension and preparation method thereof | |
| CN101766676B (en) | Extract of Albizia chinensis (Osbeck) Merr, preparation method, combination and purpose thereof | |
| CN101120969A (en) | Medicine for treating diabetes and its complications and preparing method thereof | |
| CN101053598B (en) | Medicinal composition for treating cardio-cerebralvascular diseases and diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20090513 |